FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2576088627> ?p ?o ?g. }

• W2576088627 abstract "Abstract Abstract 4517 Background: Defibrotide has recently been successfully used to treat veno-occlusive disease (VOD). We report the use of intravenous defibrotide for VOD prophylaxis in 49 patients who received hematopoietic stem cell transplantation (HSCT). This group was compared with a control group of 49 patients who underwent HSCT without defibrotide prophylaxis. Patients and methods: Data were collected retrospectively on 98 patients undergoing HSCT at the National Cancer Center, Goyang, Korea, between August 2005 and July 2008. During this period, defibrotide was randomly supplied to 49 patients free of charge by the compassionate use program. For 49 patients, VOD prophylaxis with 200 to 400 mg of defibrotide (25 mg/kg/day in children weighing less than 30 kg) administered intravenously 3 or 4 times daily was initiated from the start of conditioning and continued until 28 days post-HSCT. Results: VOD was diagnosed in 5 of 98 total patients (5.1%) at a median of 11 days post-HSCT (range: 10–14 days). VOD was graded as mild in 2 patients, moderate in 1, and severe in 2. The incidences of engraftment syndrome, thrombotic microangiopathy and VOD were not significantly different between the defibrotide group and the control group, although absolute incidences of each syndrome were lower in the defibrotide group. Patients who received prophylactic defibrotide showed earlier platelet engraftment (p<0.01) and lower activated prothrombin time (p=0.02) after HSCT. There was no day 100 treatment-related mortality (TRM) in the defibrotide group. Day 100 TRM occurred in two patients who did not receive defibrotide for VOD prophylaxis during allogeneic HSCT. Each patient was diagnosed with mild or severe VOD, and the direct causes of death were infection or VOD. Of the patients who were diagnosed with VOD, the overall survival at 100 days post HSCT was significantly higher in the defibrotide group compared to the control group (100% vs. 33.3 ± 27.2%, p<0.01). Defibrotide was well tolerated and was not discontinued in any patients. There was no grade 3 or 4 toxicity related to defibrotide or any worsening of clinical bleeding. Conclusions: Our data showed that the use of prophylactic defibrotide is safe and may have beneficial effects of defibrotide on hepatic endothelial damage following HSCT, with no TRM in defibrotide group. Considering there is no consensus on when to start treatment if a patient shows clinical features suggesting VOD, it could be important to use prophylactic defibrotide in advance for improved VOD outcomes. Disclosures: No relevant conflicts of interest to declare." @default.
• W2576088627 created "2017-01-26" @default.
• W2576088627 creator A5005515632 @default.
• W2576088627 creator A5009699134 @default.
• W2576088627 creator A5014211951 @default.
• W2576088627 creator A5036871510 @default.
• W2576088627 creator A5049507336 @default.
• W2576088627 creator A5076088179 @default.
• W2576088627 creator A5081712437 @default.
• W2576088627 creator A5081813546 @default.
• W2576088627 creator A5074113316 @default.
• W2576088627 date "2011-11-18" @default.
• W2576088627 modified "2023-09-30" @default.
• W2576088627 title "Effects of Prophylactic Defibrotide for Veno-Occlusive Disease in Hematopoietic Stem Cell Transplantation" @default.
• W2576088627 doi "https://doi.org/10.1182/blood.v118.21.4517.4517" @default.
• W2576088627 hasPublicationYear "2011" @default.
• W2576088627 type Work @default.
• W2576088627 sameAs 2576088627 @default.
• W2576088627 citedByCount "0" @default.
• W2576088627 crossrefType "journal-article" @default.
• W2576088627 hasAuthorship W2576088627A5005515632 @default.
• W2576088627 hasAuthorship W2576088627A5009699134 @default.
• W2576088627 hasAuthorship W2576088627A5014211951 @default.
• W2576088627 hasAuthorship W2576088627A5036871510 @default.
• W2576088627 hasAuthorship W2576088627A5049507336 @default.
• W2576088627 hasAuthorship W2576088627A5074113316 @default.
• W2576088627 hasAuthorship W2576088627A5076088179 @default.
• W2576088627 hasAuthorship W2576088627A5081712437 @default.
• W2576088627 hasAuthorship W2576088627A5081813546 @default.
• W2576088627 hasConcept C126322002 @default.
• W2576088627 hasConcept C141071460 @default.
• W2576088627 hasConcept C2777408962 @default.
• W2576088627 hasConcept C2777712501 @default.
• W2576088627 hasConcept C2777878052 @default.
• W2576088627 hasConcept C2779134260 @default.
• W2576088627 hasConcept C2780895475 @default.
• W2576088627 hasConcept C2911091166 @default.
• W2576088627 hasConcept C71924100 @default.
• W2576088627 hasConceptScore W2576088627C126322002 @default.
• W2576088627 hasConceptScore W2576088627C141071460 @default.
• W2576088627 hasConceptScore W2576088627C2777408962 @default.
• W2576088627 hasConceptScore W2576088627C2777712501 @default.
• W2576088627 hasConceptScore W2576088627C2777878052 @default.
• W2576088627 hasConceptScore W2576088627C2779134260 @default.
• W2576088627 hasConceptScore W2576088627C2780895475 @default.
• W2576088627 hasConceptScore W2576088627C2911091166 @default.
• W2576088627 hasConceptScore W2576088627C71924100 @default.
• W2576088627 hasLocation W25760886271 @default.
• W2576088627 hasOpenAccess W2576088627 @default.
• W2576088627 hasPrimaryLocation W25760886271 @default.
• W2576088627 hasRelatedWork W1965298744 @default.
• W2576088627 hasRelatedWork W1984256461 @default.
• W2576088627 hasRelatedWork W2025891049 @default.
• W2576088627 hasRelatedWork W2071207670 @default.
• W2576088627 hasRelatedWork W2126448937 @default.
• W2576088627 hasRelatedWork W2302063530 @default.
• W2576088627 hasRelatedWork W2342148351 @default.
• W2576088627 hasRelatedWork W2531016723 @default.
• W2576088627 hasRelatedWork W2557705598 @default.
• W2576088627 hasRelatedWork W2565581408 @default.
• W2576088627 hasRelatedWork W2570676655 @default.
• W2576088627 hasRelatedWork W2590437609 @default.
• W2576088627 hasRelatedWork W2593577562 @default.
• W2576088627 hasRelatedWork W2603733711 @default.
• W2576088627 hasRelatedWork W2763723942 @default.
• W2576088627 hasRelatedWork W2788954039 @default.
• W2576088627 hasRelatedWork W2803440649 @default.
• W2576088627 hasRelatedWork W2805170187 @default.
• W2576088627 hasRelatedWork W3081093811 @default.
• W2576088627 hasRelatedWork W3087643669 @default.
• W2576088627 isParatext "false" @default.
• W2576088627 isRetracted "false" @default.
• W2576088627 magId "2576088627" @default.
• W2576088627 workType "article" @default.